nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR2B—Sorafenib—thyroid cancer	0.41	0.575	CbGbCtD
Dihydroergotamine—ABCB1—Sorafenib—thyroid cancer	0.085	0.119	CbGbCtD
Dihydroergotamine—CYP3A4—Vandetanib—thyroid cancer	0.0845	0.118	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—thyroid cancer	0.0516	0.0723	CbGbCtD
Dihydroergotamine—CYP3A4—Sorafenib—thyroid cancer	0.0509	0.0714	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—thyroid cancer	0.0309	0.0433	CbGbCtD
Dihydroergotamine—Cystitis noninfective—Vandetanib—thyroid cancer	0.00576	0.0201	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Vandetanib—thyroid cancer	0.00569	0.0199	CcSEcCtD
Dihydroergotamine—Cystitis—Vandetanib—thyroid cancer	0.00569	0.0199	CcSEcCtD
Dihydroergotamine—Bladder pain—Vandetanib—thyroid cancer	0.00533	0.0186	CcSEcCtD
Dihydroergotamine—Myocardial ischaemia—Sorafenib—thyroid cancer	0.00495	0.0173	CcSEcCtD
Dihydroergotamine—Rash papular—Epirubicin—thyroid cancer	0.00395	0.0138	CcSEcCtD
Dihydroergotamine—Influenza like illness—Sorafenib—thyroid cancer	0.00386	0.0135	CcSEcCtD
Dihydroergotamine—Dysphagia—Vandetanib—thyroid cancer	0.0037	0.0129	CcSEcCtD
Dihydroergotamine—Rash papular—Doxorubicin—thyroid cancer	0.00365	0.0127	CcSEcCtD
Dihydroergotamine—Bronchospasm—Vandetanib—thyroid cancer	0.00364	0.0127	CcSEcCtD
Dihydroergotamine—Bronchitis—Vandetanib—thyroid cancer	0.00356	0.0124	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00344	0.012	CcSEcCtD
Dihydroergotamine—Pollakiuria—Vandetanib—thyroid cancer	0.00342	0.0119	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Vandetanib—thyroid cancer	0.00321	0.0112	CcSEcCtD
Dihydroergotamine—Epistaxis—Vandetanib—thyroid cancer	0.00311	0.0109	CcSEcCtD
Dihydroergotamine—Sinusitis—Vandetanib—thyroid cancer	0.00309	0.0108	CcSEcCtD
Dihydroergotamine—Visual impairment—Vandetanib—thyroid cancer	0.00285	0.00996	CcSEcCtD
Dihydroergotamine—Dysphagia—Sorafenib—thyroid cancer	0.0025	0.00871	CcSEcCtD
Dihydroergotamine—Muscle spasms—Vandetanib—thyroid cancer	0.00248	0.00865	CcSEcCtD
Dihydroergotamine—Tremor—Vandetanib—thyroid cancer	0.00241	0.00843	CcSEcCtD
Dihydroergotamine—Parosmia—Epirubicin—thyroid cancer	0.00227	0.00791	CcSEcCtD
Dihydroergotamine—Hypertension—Vandetanib—thyroid cancer	0.00223	0.00777	CcSEcCtD
Dihydroergotamine—Arthralgia—Vandetanib—thyroid cancer	0.00219	0.00766	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00219	0.00765	CcSEcCtD
Dihydroergotamine—Anxiety—Vandetanib—thyroid cancer	0.00219	0.00763	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Sorafenib—thyroid cancer	0.00218	0.00761	CcSEcCtD
Dihydroergotamine—Dry mouth—Vandetanib—thyroid cancer	0.00215	0.00749	CcSEcCtD
Dihydroergotamine—Oedema—Vandetanib—thyroid cancer	0.0021	0.00734	CcSEcCtD
Dihydroergotamine—Epistaxis—Sorafenib—thyroid cancer	0.0021	0.00732	CcSEcCtD
Dihydroergotamine—Parosmia—Doxorubicin—thyroid cancer	0.0021	0.00732	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00192	0.00669	CcSEcCtD
Dihydroergotamine—Insomnia—Vandetanib—thyroid cancer	0.0019	0.00664	CcSEcCtD
Dihydroergotamine—Paraesthesia—Vandetanib—thyroid cancer	0.00189	0.00659	CcSEcCtD
Dihydroergotamine—Dyspnoea—Vandetanib—thyroid cancer	0.00188	0.00654	CcSEcCtD
Dihydroergotamine—Tinnitus—Sorafenib—thyroid cancer	0.00186	0.0065	CcSEcCtD
Dihydroergotamine—Flushing—Sorafenib—thyroid cancer	0.00185	0.00647	CcSEcCtD
Dihydroergotamine—Dyspepsia—Vandetanib—thyroid cancer	0.00185	0.00646	CcSEcCtD
Dihydroergotamine—Decreased appetite—Vandetanib—thyroid cancer	0.00183	0.00638	CcSEcCtD
Dihydroergotamine—Fatigue—Vandetanib—thyroid cancer	0.00181	0.00633	CcSEcCtD
Dihydroergotamine—Rigors—Epirubicin—thyroid cancer	0.0018	0.00628	CcSEcCtD
Dihydroergotamine—Pain—Vandetanib—thyroid cancer	0.0018	0.00628	CcSEcCtD
Dihydroergotamine—Petechiae—Epirubicin—thyroid cancer	0.00179	0.00623	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00172	0.006	CcSEcCtD
Dihydroergotamine—Muscle spasms—Sorafenib—thyroid cancer	0.00167	0.00583	CcSEcCtD
Dihydroergotamine—Rigors—Doxorubicin—thyroid cancer	0.00167	0.00581	CcSEcCtD
Dihydroergotamine—Body temperature increased—Vandetanib—thyroid cancer	0.00166	0.0058	CcSEcCtD
Dihydroergotamine—Abdominal pain—Vandetanib—thyroid cancer	0.00166	0.0058	CcSEcCtD
Dihydroergotamine—Petechiae—Doxorubicin—thyroid cancer	0.00165	0.00577	CcSEcCtD
Dihydroergotamine—Herpes simplex—Epirubicin—thyroid cancer	0.00159	0.00557	CcSEcCtD
Dihydroergotamine—Asthenia—Vandetanib—thyroid cancer	0.00151	0.00527	CcSEcCtD
Dihydroergotamine—Gait disturbance—Epirubicin—thyroid cancer	0.00151	0.00526	CcSEcCtD
Dihydroergotamine—Hypertension—Sorafenib—thyroid cancer	0.0015	0.00524	CcSEcCtD
Dihydroergotamine—Pruritus—Vandetanib—thyroid cancer	0.00149	0.00519	CcSEcCtD
Dihydroergotamine—Myalgia—Sorafenib—thyroid cancer	0.00148	0.00517	CcSEcCtD
Dihydroergotamine—Arthralgia—Sorafenib—thyroid cancer	0.00148	0.00517	CcSEcCtD
Dihydroergotamine—Herpes simplex—Doxorubicin—thyroid cancer	0.00148	0.00515	CcSEcCtD
Dihydroergotamine—Ventricular tachycardia—Epirubicin—thyroid cancer	0.00147	0.00513	CcSEcCtD
Dihydroergotamine—Hiccups—Epirubicin—thyroid cancer	0.00147	0.00513	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Epirubicin—thyroid cancer	0.00147	0.00513	CcSEcCtD
Dihydroergotamine—Dry mouth—Sorafenib—thyroid cancer	0.00145	0.00505	CcSEcCtD
Dihydroergotamine—Diarrhoea—Vandetanib—thyroid cancer	0.00144	0.00502	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Epirubicin—thyroid cancer	0.00144	0.00501	CcSEcCtD
Dihydroergotamine—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00143	0.00498	CcSEcCtD
Dihydroergotamine—Influenza like illness—Epirubicin—thyroid cancer	0.00143	0.00498	CcSEcCtD
Dihydroergotamine—Cystitis—Epirubicin—thyroid cancer	0.00142	0.00495	CcSEcCtD
Dihydroergotamine—Shock—Sorafenib—thyroid cancer	0.0014	0.00487	CcSEcCtD
Dihydroergotamine—Gait disturbance—Doxorubicin—thyroid cancer	0.00139	0.00486	CcSEcCtD
Dihydroergotamine—Dizziness—Vandetanib—thyroid cancer	0.00139	0.00485	CcSEcCtD
Dihydroergotamine—Vaginal infection—Epirubicin—thyroid cancer	0.00139	0.00484	CcSEcCtD
Dihydroergotamine—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00136	0.00475	CcSEcCtD
Dihydroergotamine—Hiccups—Doxorubicin—thyroid cancer	0.00136	0.00475	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Doxorubicin—thyroid cancer	0.00136	0.00475	CcSEcCtD
Dihydroergotamine—Anorexia—Sorafenib—thyroid cancer	0.00135	0.00472	CcSEcCtD
Dihydroergotamine—Vomiting—Vandetanib—thyroid cancer	0.00134	0.00467	CcSEcCtD
Dihydroergotamine—Bladder pain—Epirubicin—thyroid cancer	0.00133	0.00464	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00133	0.00464	CcSEcCtD
Dihydroergotamine—Rash—Vandetanib—thyroid cancer	0.00133	0.00463	CcSEcCtD
Dihydroergotamine—Dermatitis—Vandetanib—thyroid cancer	0.00133	0.00462	CcSEcCtD
Dihydroergotamine—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00132	0.00461	CcSEcCtD
Dihydroergotamine—Influenza like illness—Doxorubicin—thyroid cancer	0.00132	0.00461	CcSEcCtD
Dihydroergotamine—Headache—Vandetanib—thyroid cancer	0.00132	0.0046	CcSEcCtD
Dihydroergotamine—Cystitis—Doxorubicin—thyroid cancer	0.00131	0.00458	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00129	0.00451	CcSEcCtD
Dihydroergotamine—Vaginal infection—Doxorubicin—thyroid cancer	0.00128	0.00448	CcSEcCtD
Dihydroergotamine—Abnormal vision—Epirubicin—thyroid cancer	0.00128	0.00447	CcSEcCtD
Dihydroergotamine—Mental disability—Epirubicin—thyroid cancer	0.00128	0.00445	CcSEcCtD
Dihydroergotamine—Dyspnoea—Sorafenib—thyroid cancer	0.00127	0.00441	CcSEcCtD
Dihydroergotamine—Nausea—Vandetanib—thyroid cancer	0.00125	0.00436	CcSEcCtD
Dihydroergotamine—Dyspepsia—Sorafenib—thyroid cancer	0.00125	0.00436	CcSEcCtD
Dihydroergotamine—Decreased appetite—Sorafenib—thyroid cancer	0.00123	0.0043	CcSEcCtD
Dihydroergotamine—Bladder pain—Doxorubicin—thyroid cancer	0.00123	0.00429	CcSEcCtD
Dihydroergotamine—Fatigue—Sorafenib—thyroid cancer	0.00122	0.00427	CcSEcCtD
Dihydroergotamine—Pain—Sorafenib—thyroid cancer	0.00121	0.00423	CcSEcCtD
Dihydroergotamine—Abnormal vision—Doxorubicin—thyroid cancer	0.00119	0.00414	CcSEcCtD
Dihydroergotamine—Eye pain—Epirubicin—thyroid cancer	0.00118	0.00412	CcSEcCtD
Dihydroergotamine—Mental disability—Doxorubicin—thyroid cancer	0.00118	0.00412	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00116	0.00405	CcSEcCtD
Dihydroergotamine—Hot flush—Epirubicin—thyroid cancer	0.00114	0.00398	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Epirubicin—thyroid cancer	0.00113	0.00395	CcSEcCtD
Dihydroergotamine—Urticaria—Sorafenib—thyroid cancer	0.00113	0.00393	CcSEcCtD
Dihydroergotamine—Abdominal pain—Sorafenib—thyroid cancer	0.00112	0.00391	CcSEcCtD
Dihydroergotamine—Body temperature increased—Sorafenib—thyroid cancer	0.00112	0.00391	CcSEcCtD
Dihydroergotamine—Eye pain—Doxorubicin—thyroid cancer	0.00109	0.00382	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00109	0.0038	CcSEcCtD
Dihydroergotamine—Hot flush—Doxorubicin—thyroid cancer	0.00106	0.00368	CcSEcCtD
Dihydroergotamine—Migraine—Epirubicin—thyroid cancer	0.00105	0.00366	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00105	0.00365	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Sorafenib—thyroid cancer	0.00105	0.00365	CcSEcCtD
Dihydroergotamine—Face oedema—Epirubicin—thyroid cancer	0.00103	0.00359	CcSEcCtD
Dihydroergotamine—Asthenia—Sorafenib—thyroid cancer	0.00102	0.00355	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00101	0.00352	CcSEcCtD
Dihydroergotamine—Pruritus—Sorafenib—thyroid cancer	0.001	0.0035	CcSEcCtD
Dihydroergotamine—Migraine—Doxorubicin—thyroid cancer	0.000972	0.00339	CcSEcCtD
Dihydroergotamine—Diarrhoea—Sorafenib—thyroid cancer	0.000971	0.00339	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—thyroid cancer	0.000953	0.00333	CcSEcCtD
Dihydroergotamine—Muscular weakness—Epirubicin—thyroid cancer	0.000941	0.00328	CcSEcCtD
Dihydroergotamine—Dizziness—Sorafenib—thyroid cancer	0.000938	0.00327	CcSEcCtD
Dihydroergotamine—Dysphagia—Epirubicin—thyroid cancer	0.000922	0.00322	CcSEcCtD
Dihydroergotamine—Vomiting—Sorafenib—thyroid cancer	0.000902	0.00315	CcSEcCtD
Dihydroergotamine—Angina pectoris—Epirubicin—thyroid cancer	0.000898	0.00313	CcSEcCtD
Dihydroergotamine—Rash—Sorafenib—thyroid cancer	0.000895	0.00312	CcSEcCtD
Dihydroergotamine—Dermatitis—Sorafenib—thyroid cancer	0.000894	0.00312	CcSEcCtD
Dihydroergotamine—Headache—Sorafenib—thyroid cancer	0.000889	0.0031	CcSEcCtD
Dihydroergotamine—Bronchitis—Epirubicin—thyroid cancer	0.000887	0.00309	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—thyroid cancer	0.000871	0.00304	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000857	0.00299	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—thyroid cancer	0.000853	0.00298	CcSEcCtD
Dihydroergotamine—Pollakiuria—Epirubicin—thyroid cancer	0.000852	0.00297	CcSEcCtD
Dihydroergotamine—Nausea—Sorafenib—thyroid cancer	0.000843	0.00294	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—thyroid cancer	0.000831	0.0029	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—thyroid cancer	0.000821	0.00286	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—thyroid cancer	0.000799	0.00279	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000793	0.00277	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—thyroid cancer	0.000788	0.00275	CcSEcCtD
Dihydroergotamine—Epistaxis—Epirubicin—thyroid cancer	0.000776	0.00271	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—thyroid cancer	0.000771	0.00269	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—thyroid cancer	0.00074	0.00258	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—thyroid cancer	0.000739	0.00258	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000734	0.00256	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—thyroid cancer	0.000733	0.00256	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—thyroid cancer	0.000718	0.0025	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—thyroid cancer	0.000714	0.00249	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—thyroid cancer	0.000711	0.00248	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—thyroid cancer	0.000688	0.0024	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—thyroid cancer	0.000685	0.00239	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—thyroid cancer	0.000685	0.00239	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00068	0.00237	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—thyroid cancer	0.000678	0.00237	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—thyroid cancer	0.000662	0.00231	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—thyroid cancer	0.000658	0.0023	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—thyroid cancer	0.000637	0.00222	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—thyroid cancer	0.000634	0.00221	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—thyroid cancer	0.000631	0.0022	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—thyroid cancer	0.000624	0.00218	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—thyroid cancer	0.000618	0.00216	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—thyroid cancer	0.000613	0.00214	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000596	0.00208	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—thyroid cancer	0.00059	0.00206	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—thyroid cancer	0.000583	0.00204	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—thyroid cancer	0.000579	0.00202	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—thyroid cancer	0.000577	0.00202	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—thyroid cancer	0.000577	0.00201	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—thyroid cancer	0.000572	0.00199	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—thyroid cancer	0.000568	0.00198	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—thyroid cancer	0.000555	0.00194	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000552	0.00193	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—thyroid cancer	0.000547	0.00191	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—thyroid cancer	0.000547	0.00191	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—thyroid cancer	0.000546	0.00191	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—thyroid cancer	0.000545	0.0019	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—thyroid cancer	0.00054	0.00189	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—thyroid cancer	0.000536	0.00187	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—thyroid cancer	0.000535	0.00187	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—thyroid cancer	0.000534	0.00186	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—thyroid cancer	0.000529	0.00185	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—thyroid cancer	0.000525	0.00183	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—thyroid cancer	0.000524	0.00183	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—thyroid cancer	0.000516	0.0018	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—thyroid cancer	0.000513	0.00179	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—thyroid cancer	0.000512	0.00179	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000507	0.00177	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—thyroid cancer	0.000506	0.00177	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—thyroid cancer	0.000506	0.00177	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—thyroid cancer	0.000504	0.00176	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—thyroid cancer	0.0005	0.00175	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—thyroid cancer	0.0005	0.00174	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—thyroid cancer	0.000495	0.00173	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—thyroid cancer	0.00049	0.00171	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—thyroid cancer	0.000489	0.00171	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—thyroid cancer	0.000485	0.00169	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000478	0.00167	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—thyroid cancer	0.000477	0.00167	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—thyroid cancer	0.000474	0.00166	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—thyroid cancer	0.000474	0.00165	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—thyroid cancer	0.000471	0.00164	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000469	0.00164	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—thyroid cancer	0.000468	0.00163	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—thyroid cancer	0.000466	0.00163	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—thyroid cancer	0.000463	0.00161	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—thyroid cancer	0.000462	0.00161	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—thyroid cancer	0.000456	0.00159	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—thyroid cancer	0.000453	0.00158	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—thyroid cancer	0.000452	0.00158	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—thyroid cancer	0.000448	0.00156	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000442	0.00154	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—thyroid cancer	0.000439	0.00153	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—thyroid cancer	0.000436	0.00152	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—thyroid cancer	0.000433	0.00151	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—thyroid cancer	0.000432	0.00151	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—thyroid cancer	0.000431	0.00151	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000429	0.0015	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—thyroid cancer	0.000427	0.00149	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—thyroid cancer	0.000422	0.00147	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—thyroid cancer	0.000418	0.00146	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—thyroid cancer	0.000417	0.00145	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—thyroid cancer	0.000415	0.00145	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—thyroid cancer	0.000415	0.00145	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—thyroid cancer	0.000415	0.00145	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—thyroid cancer	0.0004	0.0014	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000397	0.00138	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—thyroid cancer	0.000386	0.00135	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—thyroid cancer	0.000385	0.00135	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—thyroid cancer	0.000384	0.00134	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—thyroid cancer	0.000384	0.00134	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—thyroid cancer	0.000376	0.00131	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—thyroid cancer	0.000371	0.00129	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—thyroid cancer	0.000359	0.00125	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000357	0.00125	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—thyroid cancer	0.000348	0.00121	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—thyroid cancer	0.000347	0.00121	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—thyroid cancer	0.000343	0.0012	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—thyroid cancer	0.000333	0.00116	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—thyroid cancer	0.000332	0.00116	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—thyroid cancer	0.000331	0.00115	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—thyroid cancer	0.00033	0.00115	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—thyroid cancer	0.000329	0.00115	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—thyroid cancer	0.000321	0.00112	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—thyroid cancer	0.000311	0.00109	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—thyroid cancer	0.000309	0.00108	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—thyroid cancer	0.000306	0.00107	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—thyroid cancer	0.000306	0.00107	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—thyroid cancer	0.000304	0.00106	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—thyroid cancer	0.000288	0.00101	CcSEcCtD
Dihydroergotamine—HTR2B—Signaling by GPCR—TSHR—thyroid cancer	5.37e-07	0.0027	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PRKAR1A—thyroid cancer	5.29e-07	0.00266	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TRIM33—thyroid cancer	5.27e-07	0.00265	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CHST14—thyroid cancer	5.23e-07	0.00263	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—SST—thyroid cancer	5.19e-07	0.00261	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—SST—thyroid cancer	5.04e-07	0.00253	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PTCH1—thyroid cancer	5.01e-07	0.00252	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—SST—thyroid cancer	5e-07	0.00251	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CALCA—thyroid cancer	5e-07	0.00251	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PTCH1—thyroid cancer	4.97e-07	0.0025	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—SST—thyroid cancer	4.9e-07	0.00246	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PTCH1—thyroid cancer	4.86e-07	0.00244	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CALCA—thyroid cancer	4.85e-07	0.00244	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CALCA—thyroid cancer	4.82e-07	0.00242	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—TSHR—thyroid cancer	4.8e-07	0.00241	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TCF7L1—thyroid cancer	4.75e-07	0.00239	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CALCA—thyroid cancer	4.72e-07	0.00237	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TCF7L1—thyroid cancer	4.71e-07	0.00237	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TCF7L1—thyroid cancer	4.62e-07	0.00232	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—SST—thyroid cancer	4.6e-07	0.00231	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—SST—thyroid cancer	4.58e-07	0.0023	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PTCH1—thyroid cancer	4.57e-07	0.0023	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—SST—thyroid cancer	4.54e-07	0.00228	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MINPP1—thyroid cancer	4.52e-07	0.00227	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	4.51e-07	0.00227	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—SST—thyroid cancer	4.45e-07	0.00224	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CALCA—thyroid cancer	4.43e-07	0.00223	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CALCA—thyroid cancer	4.41e-07	0.00221	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CALCA—thyroid cancer	4.37e-07	0.0022	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CALCB—thyroid cancer	4.37e-07	0.0022	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—TSHR—thyroid cancer	4.36e-07	0.00219	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TCF7L1—thyroid cancer	4.34e-07	0.00218	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PRKAR1A—thyroid cancer	4.29e-07	0.00215	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CALCA—thyroid cancer	4.28e-07	0.00215	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—HPGD—thyroid cancer	4.21e-07	0.00212	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—SST—thyroid cancer	4.18e-07	0.0021	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TRIM33—thyroid cancer	4.14e-07	0.00208	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CALCA—thyroid cancer	4.02e-07	0.00202	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CDK1—thyroid cancer	3.99e-07	0.002	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CDK1—thyroid cancer	3.96e-07	0.00199	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IFNA2—thyroid cancer	3.89e-07	0.00195	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	3.88e-07	0.00195	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CDK1—thyroid cancer	3.88e-07	0.00195	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NDUFA13—thyroid cancer	3.84e-07	0.00193	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—RXRA—thyroid cancer	3.79e-07	0.00191	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—TSHR—thyroid cancer	3.77e-07	0.0019	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—SST—thyroid cancer	3.73e-07	0.00188	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PTCH1—thyroid cancer	3.71e-07	0.00186	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CDK1—thyroid cancer	3.64e-07	0.00183	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CHST14—thyroid cancer	3.61e-07	0.00182	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CALCA—thyroid cancer	3.59e-07	0.00181	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	3.57e-07	0.0018	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	3.57e-07	0.0018	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TCF7L1—thyroid cancer	3.52e-07	0.00177	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	3.51e-07	0.00177	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TSHR—thyroid cancer	3.48e-07	0.00175	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TSHR—thyroid cancer	3.45e-07	0.00173	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—TSHR—thyroid cancer	3.42e-07	0.00172	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PRKAR1A—thyroid cancer	3.42e-07	0.00172	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PRKAR1A—thyroid cancer	3.4e-07	0.00171	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—SST—thyroid cancer	3.39e-07	0.0017	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TSHR—thyroid cancer	3.38e-07	0.0017	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PRKAR1A—thyroid cancer	3.37e-07	0.00169	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PRKAR1A—thyroid cancer	3.32e-07	0.00167	CbGpPWpGaD
Dihydroergotamine—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	3.31e-07	0.00166	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	3.3e-07	0.00166	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MEN1—thyroid cancer	3.27e-07	0.00164	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CALCA—thyroid cancer	3.26e-07	0.00164	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MEN1—thyroid cancer	3.24e-07	0.00163	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MEN1—thyroid cancer	3.18e-07	0.0016	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TSHR—thyroid cancer	3.17e-07	0.0016	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PRKAR1A—thyroid cancer	3.12e-07	0.00157	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MEN1—thyroid cancer	2.98e-07	0.0015	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTCH1—thyroid cancer	2.96e-07	0.00149	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CDK1—thyroid cancer	2.95e-07	0.00148	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTCH1—thyroid cancer	2.93e-07	0.00147	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—SST—thyroid cancer	2.93e-07	0.00147	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HPGD—thyroid cancer	2.91e-07	0.00146	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PTCH1—thyroid cancer	2.91e-07	0.00146	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTCH1—thyroid cancer	2.87e-07	0.00144	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CALCA—thyroid cancer	2.82e-07	0.00142	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	2.81e-07	0.00141	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MINPP1—thyroid cancer	2.79e-07	0.0014	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TCF7L1—thyroid cancer	2.76e-07	0.00139	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SST—thyroid cancer	2.7e-07	0.00136	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTCH1—thyroid cancer	2.7e-07	0.00136	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SST—thyroid cancer	2.68e-07	0.00135	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.67e-07	0.00134	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—SST—thyroid cancer	2.66e-07	0.00134	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SST—thyroid cancer	2.63e-07	0.00132	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CALCA—thyroid cancer	2.6e-07	0.00131	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CALCA—thyroid cancer	2.58e-07	0.0013	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TSHR—thyroid cancer	2.57e-07	0.00129	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CALCA—thyroid cancer	2.56e-07	0.00129	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	2.54e-07	0.00128	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRKAR1A—thyroid cancer	2.53e-07	0.00127	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CALCA—thyroid cancer	2.53e-07	0.00127	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SST—thyroid cancer	2.47e-07	0.00124	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.45e-07	0.00123	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MEN1—thyroid cancer	2.42e-07	0.00122	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—TPR—thyroid cancer	2.42e-07	0.00122	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PRKAR1A—thyroid cancer	2.38e-07	0.0012	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CALCA—thyroid cancer	2.38e-07	0.00119	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.37e-07	0.00119	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDK1—thyroid cancer	2.36e-07	0.00118	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDK1—thyroid cancer	2.34e-07	0.00118	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CDK1—thyroid cancer	2.32e-07	0.00117	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDK1—thyroid cancer	2.29e-07	0.00115	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.25e-07	0.00113	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CHST14—thyroid cancer	2.23e-07	0.00112	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTCH1—thyroid cancer	2.19e-07	0.0011	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDK1—thyroid cancer	2.15e-07	0.00108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TSHR—thyroid cancer	2.02e-07	0.00102	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SST—thyroid cancer	2e-07	0.00101	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKAR1A—thyroid cancer	1.99e-07	0.001	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CALCA—thyroid cancer	1.93e-07	0.000968	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MEN1—thyroid cancer	1.9e-07	0.000956	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NRG1—thyroid cancer	1.89e-07	0.000951	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	1.88e-07	0.000946	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NRG1—thyroid cancer	1.88e-07	0.000943	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NRG1—thyroid cancer	1.84e-07	0.000924	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.82e-07	0.000914	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—SLC5A5—thyroid cancer	1.81e-07	0.00091	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HPGD—thyroid cancer	1.79e-07	0.000902	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDK1—thyroid cancer	1.74e-07	0.000877	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NRG1—thyroid cancer	1.73e-07	0.000868	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTCH1—thyroid cancer	1.72e-07	0.000865	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TERT—thyroid cancer	1.7e-07	0.000854	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TERT—thyroid cancer	1.69e-07	0.000847	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TPR—thyroid cancer	1.67e-07	0.000841	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.67e-07	0.000841	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TERT—thyroid cancer	1.65e-07	0.000829	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.65e-07	0.000827	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HIF1A—thyroid cancer	1.62e-07	0.000816	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HIF1A—thyroid cancer	1.61e-07	0.00081	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HIF1A—thyroid cancer	1.58e-07	0.000793	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SST—thyroid cancer	1.57e-07	0.000791	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TERT—thyroid cancer	1.55e-07	0.000779	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—RXRA—thyroid cancer	1.52e-07	0.000765	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CALCA—thyroid cancer	1.51e-07	0.000761	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HIF1A—thyroid cancer	1.48e-07	0.000745	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—NRAS—thyroid cancer	1.45e-07	0.000729	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—NRAS—thyroid cancer	1.43e-07	0.000719	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—NRAS—thyroid cancer	1.42e-07	0.000714	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.41e-07	0.00071	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NRG1—thyroid cancer	1.4e-07	0.000704	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—NRAS—thyroid cancer	1.39e-07	0.000699	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDK1—thyroid cancer	1.37e-07	0.000689	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—BRAF—thyroid cancer	1.34e-07	0.000676	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—BRAF—thyroid cancer	1.33e-07	0.000671	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—BRAF—thyroid cancer	1.31e-07	0.000657	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—NRAS—thyroid cancer	1.31e-07	0.000656	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TERT—thyroid cancer	1.26e-07	0.000632	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.25e-07	0.000629	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—KRAS—thyroid cancer	1.25e-07	0.000627	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—KRAS—thyroid cancer	1.23e-07	0.000619	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—BRAF—thyroid cancer	1.23e-07	0.000617	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—KRAS—thyroid cancer	1.22e-07	0.000614	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HIF1A—thyroid cancer	1.2e-07	0.000604	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—KRAS—thyroid cancer	1.2e-07	0.000601	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—KRAS—thyroid cancer	1.12e-07	0.000565	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—thyroid cancer	1.11e-07	0.000558	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NRG1—thyroid cancer	1.1e-07	0.000553	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—HRAS—thyroid cancer	1.06e-07	0.000533	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	1.06e-07	0.000532	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—RXRA—thyroid cancer	1.05e-07	0.000529	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HRAS—thyroid cancer	1.05e-07	0.000526	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HRAS—thyroid cancer	1.04e-07	0.000522	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TPR—thyroid cancer	1.03e-07	0.000518	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	1.02e-07	0.000512	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HRAS—thyroid cancer	1.02e-07	0.000511	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.01e-07	0.00051	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—thyroid cancer	1.01e-07	0.000508	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BRAF—thyroid cancer	9.96e-08	0.0005	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—thyroid cancer	9.89e-08	0.000497	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—thyroid cancer	9.88e-08	0.000497	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—thyroid cancer	9.82e-08	0.000493	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—thyroid cancer	9.74e-08	0.00049	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—thyroid cancer	9.61e-08	0.000483	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HRAS—thyroid cancer	9.55e-08	0.00048	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—thyroid cancer	9.54e-08	0.000479	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTEN—thyroid cancer	9.47e-08	0.000476	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	9.45e-08	0.000475	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTEN—thyroid cancer	9.4e-08	0.000473	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—thyroid cancer	9.37e-08	0.000471	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—thyroid cancer	9.29e-08	0.000467	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—thyroid cancer	9.24e-08	0.000465	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTEN—thyroid cancer	9.21e-08	0.000463	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—thyroid cancer	9.17e-08	0.000461	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	9.12e-08	0.000458	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	8.98e-08	0.000451	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—thyroid cancer	8.96e-08	0.00045	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTEN—thyroid cancer	8.65e-08	0.000435	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NRAS—thyroid cancer	8.45e-08	0.000425	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—thyroid cancer	8.44e-08	0.000424	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NRAS—thyroid cancer	8.39e-08	0.000422	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	8.32e-08	0.000418	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NRAS—thyroid cancer	8.21e-08	0.000413	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	7.82e-08	0.000393	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	7.75e-08	0.000389	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	7.72e-08	0.000388	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NRAS—thyroid cancer	7.72e-08	0.000388	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—thyroid cancer	7.56e-08	0.00038	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	7.53e-08	0.000379	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KRAS—thyroid cancer	7.27e-08	0.000366	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—thyroid cancer	7.27e-08	0.000365	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KRAS—thyroid cancer	7.22e-08	0.000363	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	7.16e-08	0.00036	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KRAS—thyroid cancer	7.07e-08	0.000355	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTEN—thyroid cancer	7.01e-08	0.000352	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	6.84e-08	0.000344	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—thyroid cancer	6.64e-08	0.000334	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KRAS—thyroid cancer	6.64e-08	0.000334	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTEN—thyroid cancer	6.59e-08	0.000331	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—RXRA—thyroid cancer	6.48e-08	0.000326	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—thyroid cancer	6.47e-08	0.000325	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—thyroid cancer	6.42e-08	0.000322	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—thyroid cancer	6.28e-08	0.000316	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NRAS—thyroid cancer	6.26e-08	0.000314	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HRAS—thyroid cancer	6.18e-08	0.000311	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HRAS—thyroid cancer	6.14e-08	0.000308	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	6.09e-08	0.000306	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HRAS—thyroid cancer	6.01e-08	0.000302	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	5.92e-08	0.000298	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—thyroid cancer	5.9e-08	0.000297	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	5.71e-08	0.000287	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HRAS—thyroid cancer	5.64e-08	0.000284	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	5.51e-08	0.000277	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—thyroid cancer	5.46e-08	0.000274	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—thyroid cancer	5.42e-08	0.000272	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KRAS—thyroid cancer	5.38e-08	0.000271	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	5.38e-08	0.00027	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—thyroid cancer	5.31e-08	0.000267	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—thyroid cancer	5.23e-08	0.000263	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—thyroid cancer	4.98e-08	0.00025	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	4.92e-08	0.000247	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—thyroid cancer	4.79e-08	0.000241	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HRAS—thyroid cancer	4.58e-08	0.00023	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTEN—thyroid cancer	4.56e-08	0.000229	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	4.23e-08	0.000213	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—thyroid cancer	4.09e-08	0.000206	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—thyroid cancer	4.04e-08	0.000203	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—thyroid cancer	3.8e-08	0.000191	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—thyroid cancer	3.76e-08	0.000189	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	3.6e-08	0.000181	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.22e-08	0.000162	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	3.18e-08	0.00016	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTEN—thyroid cancer	2.81e-08	0.000141	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—thyroid cancer	2.63e-08	0.000132	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—thyroid cancer	1.62e-08	8.13e-05	CbGpPWpGaD
